Financial Metrics Unveiled: Humacyte Inc (HUMA)’s Key Ratios in the Spotlight

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of Humacyte Inc (NASDAQ: HUMA) closed at $4.51 in the last session, down -3.01% from day before closing price of $4.65. In other words, the price has decreased by -$3.01 from its previous closing price. On the day, 3.55 million shares were traded. HUMA stock price reached its highest trading level at $4.7 during the session, while it also had its lowest trading level at $4.435.

Ratios:

We take a closer look at HUMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, Reiterated its Buy rating but revised its target price to $15 from $12 previously.

On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.

Piper Sandler Upgraded its Underweight to Neutral on August 14, 2023, whereas the target price for the stock was revised from $2.75 to $3.50.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’24 when Constantino Michael T. bought 4,600 shares for $4.39 per share. The transaction valued at 20,181 led to the insider holds 16,950 shares of the business.

Niklason Laura E bought 1,797 shares of HUMA for $7,979 on Nov 19 ’24. The President, CEO and Director now owns 243,851 shares after completing the transaction at $4.44 per share. On Nov 19 ’24, another insider, Dougan Brady W, who serves as the Director of the company, bought 1,797 shares for $4.44 each. As a result, the insider paid 7,979 and bolstered with 243,851 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 580292736 and an Enterprise Value of 580935040.

Stock Price History:

Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $2.48. The 50-Day Moving Average of the stock is -6.21%, while the 200-Day Moving Average is calculated to be -17.12%.

Shares Statistics:

According to the various share statistics, HUMA traded on average about 4.41M shares per day over the past 3-months and 11045210 shares per day over the past 10 days. A total of 119.84M shares are outstanding, with a floating share count of 104.37M. Insiders hold about 18.88% of the company’s shares, while institutions hold 27.90% stake in the company. Shares short for HUMA as of 1732838400 were 20333918 with a Short Ratio of 4.99, compared to 1730332800 on 17250350. Therefore, it implies a Short% of Shares Outstanding of 20333918 and a Short% of Float of 20.36.

Most Popular